Drug shown to reduce new attacks/symptom progression in some patients
In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary progressive MS.
Three studies conducted by an international team of researchers, which included Amit Bar-Or and Douglas Arnold from the Montreal Neurological Institute and Hospital of McGill University, have discovered that ocrelizumab can significantly reduce new attacks in patients with relapsing MS, as well as slow the progression of symptoms caused by primary progressive MS.
In one study, 732 patients with primary progressive MS were randomized on a 2:1 ratio to receive either ocrelizumab, a humanized monoclonal antibody that depletes CD20+ B cells, or a placebo.
The proportion of patients with 12-week confirmed disability progression was 39.3 per cent with the placebo versus 32.9 per cent with ocrelizumab. After 24 weeks, the proportion with confirmed disability progression was 35.7 per cent with placebo versus 29.6 per cent with ocrelizumab. By week 120, timed 25-foot walk worsened by 55.1 per cent for placebo versus 38.9 per cent for ocrelizumab. Patients given ocrelizumab were also found to have fewer new brain lesions and less brain volume loss than those given the placebo.
Researchers also tested ocrelizumab in two separate studies of patients with relapsing remitting MS, one a group of 821 and the other 835. In both studies, patients were randomized on a 1:1 ratio to receive either ocrelizumab or an already established treatment for relapsing MS: subcutaneous interferon-beta, injected three times weekly. Compared to the placebo, relapse rates in patients given ocrelizumab were 46-per-cent lower in one study and 47-per-cent lower in the other. Ocrelizumab was found to reduce the risk of disability progression after 12 weeks and 24 weeks, and reduced the number of new brain lesions.
The study noted that infusion-related reactions occurred in 34.3 per cent of ocrelizumab-treated patients. Serious infections were not more frequent with ocrelizumab compared to the interferon (1.3 versus 2.9 per cent respectively). Malignancies occurred in four ocrelizumab-treated patients and in two interferon-treated patients. Further observation is required to determine the long-term safety of ocrelizumab.
“The results in patients with relapsing remitting MS not only demonstrate very high efficacy against relapses, but also underscore the important emerging role of B cells of the immune system in the development of relapses,” says Bar-Or. “While the results in patients with primary progressive MS are more modest, they nonetheless represent the very first successful trial in such patients, a breakthrough as primary progressive MS now transitions from a previously untreatable condition to one that can be impacted by therapy. It is an important step forward in the field.”
These studies, funded by Roche, were published in the New England Journal of Medicine on Dec. 21, 2016.
MS in Canada
Canada has one of the world’s highest rates of MS – about 1,100 new cases each year. Some 50,000 Canadians have MS, and more than one-in-five patients are in Quebec. MS is one of the most common neurological diseases among young Canadians. Children as young as two can develop the disease. It typically strikes people in their prime years, between 15 and 40. Women are twice as likely as men to contract MS.
Learn more: Breakthrough in MS treatment
Receive an email update when we add a new MULTIPLE SCLEROSIS article.
The Latest on: Multiple sclerosis
via Google News
The Latest on: Multiple sclerosis
- Food allergies and multiple sclerosis: study reveals a new link on February 19, 2019 at 12:54 pm
Like many other medical conditions, the mechanism of multiple sclerosis remains an enigma—a puzzle composed of complex genetic and environmental factors. A key piece to this puzzle is the immune ... […]
- Food allergies and multiple sclerosis: New link on February 19, 2019 at 11:05 am
Investigating the correlation between allergy and inflammatory disease activity, a team of investigators has found new evidence connecting food allergies and relapses of multiple sclerosis. Like many ... […]
- Walk MS in Forest Park helps Multiple Sclerosis fundraising on February 19, 2019 at 6:55 am
ST. LOUIS - Multiple Sclerosis is a debilitating disease, disabling the central nervous system. A new study shows that in the US, nearly 1-million people are living with MS which is more than ... […]
- Leeds charity raising awareness of sleep problems facing people with multiple sclerosis on February 19, 2019 at 1:55 am
People living with multiple sclerosis are facing complications caused by fatigue and insomnia which are not always properly recognised by medics, a charity has warned. Shift MS, a Leeds-based support ... […]
- Aussie boxing legend pays visit to multiple sclerosis sufferer on February 18, 2019 at 7:59 pm
BOXING devotee Jim Pevitt faces a constant fight with multiple sclerosis that is tougher then any 12-rounder for a world title. And any fighter will tell you that you need good people in your corner a... […]
- Lantana event raises money to battle multiple sclerosis on February 18, 2019 at 5:30 am
LANTANA, Fla. — The community came together Sunday in Lantana to fight multiple sclerosis. The "Defeat MS Benefit Concert" took place at Lakeside Anchor Inn with live music, food, drinks and raffles. ... […]
- Downloadable Pack: Understanding Multiple Sclerosis on February 18, 2019 at 3:31 am
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry. Insid... […]
- New Study Confirms Multiple Sclerosis Prevalence in the US is Nearly 1 Million People; More Than Twice As Many As Previous Number on February 15, 2019 at 1:30 pm
NEW YORK, Feb. 15, 2019 /PRNewswire/ -- A study conducted by the National Multiple Sclerosis Society and published in the February 15, 2019, online issue of Neurology®, the medical journal of the Amer... […]
- Janice Dean: There's incredible news about my disease – Multiple sclerosis on February 15, 2019 at 1:19 pm
It’s the headline that is making all of us who live with or love someone with multiple sclerosis (MS) pay attention. There are many more of us out there than has ever been reported. Four years ago, th... […]
via Bing News